DigiStorm 2018
Friday, March 13, 2026
31.4
C
Bengaluru
Hot topics
How Did Telma Become a 1000+ Cr Brand?
The untold story of Glenmark's phenomenal success in building...
Bring Your Own Learning
Articles by K. Hariram, Vivek Hattangadi, DigiPharmaX, Satya Mahesh, Ajesh Shah and Phanish Chandra
Making Peace with an Unlived Life – My Journey by Deep Bhandari
The Beginning
I was at crossroads after completing computer...
Biologics Patent Cliff (2025–2029): A Golden Opportunity for Indian Pharma
https://www.pharmamanufacturing.com/articles/2011/095
A quiet but seismic shift is underway in global...
Breaking Performance Barriers
Articles by K. Hariram, Pankaj Mehrotra, Rinkesh Shah, Gopal Kishore, Amaninder S. Dhillon, Ramandish Arora, Mohit Kumar Bhutani, Richa Goyal, and Mahendra Kumar Rai
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
Hot topics
Is Your Field Force Sales Enabled? Are They Sales Ready?
Pankaj Gurusahani and Arun Subramanian, Co-founder of Enparadigm with...
Are Digital Pharmacies a Game Changer?
Lower prices, discounts, convenience of ordering and home delivery are some of the benefits for consumers with e-pharmacies. The anonymity of the internet encourages patients to seek information about medicines that they would otherwise avoid. Mental health is one area where the consumers wish to maintain confidentiality and opt for online consultation and medication.
Is Pharma Losing Good SalesPeople
Articles by Gopal Kishore, K. Hariram, Pankaj Mehrotra and Vivek Hattangadi
Creat Customer
Articles by K. Hariram, Hanno Wolfram, Vivek Hattangadi, Salil Kallianpur, Amit Jain, Dr. Palakodeti Ratnakar, and Pankaj Mehrotra
Will Omicron Wave be a Repeat Rx for Indian Pharma?
How had Indian Pharma responded to the challenges brought on by the Covid19 crisis and the inability to connect with doctors and other Rx influencers?
Is it back to business-as-usual or have some companies learned from their mistakes and become digital savvy?
How will Indian Pharma cope with the possibility of another lockdown and meeting restrictions looming in view of the rising Omicron wave?
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
Newsletter
Get important news delivered directly to your inbox and stay connected!